M. Mcdermott

发表

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

L. O’Driscoll, L. Liotta, V. Espina, 2018, BMC Cancer.

Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.

L. O’Driscoll, S. Rani, C. Corcoran, 2014, Cancer research.

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy

M. Henry, P. Meleady, M. Clynes, 2014, Molecular Cancer.

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells

M. Duffy, J. Crown, B. Browne, 2019, Cancers.

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells

M. Duffy, J. Crown, B. Browne, 2019, Cancers.

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

D. Slamon, S. Hurvitz, K. Rose, 2020, Breast Cancer Research.

Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo

B. Győrffy, I. Roninson, J. Crown, 2022, Proceedings of the National Academy of Sciences of the United States of America.

Concise total syntheses of (–)-jorunnamycin A and (–)-jorumycin enabled by asymmetric catalysis

D. Slamon, K. Negoro, B. Stoltz, 2019, Science.

In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies

Martin Clynes, Steven Busschots, M. Clynes, 2014, Front. Oncol..

Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer

B. Győrffy, I. Roninson, A. Chumanevich, 2017, Oncotarget.

Mechanisms of resistance to lapatinib in HER2 positive breast cancer

M. Mcdermott, M. McDermott, 2012 .